Equities

Sinovac Biotech Ltd

Sinovac Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.47
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Feb 22 2019 21:00 GMT.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

  • Revenue in USD (TTM)448.27m
  • Net income in USD-105.90m
  • Incorporated1999
  • Employees3.04k
  • Location
    Sinovac Biotech LtdNo. 39 Shangdi Xi Road, Haidian DistrictBEIJING 100085ChinaCHN
  • Phone+86 1 082890088
  • Fax+86 1 056931800
  • Websitehttp://www.sinovac.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
National Research Corporation147.42m30.36m603.86m435.0020.4016.3416.634.101.241.246.021.551.16--11.53338,896.6023.8026.2535.6736.7762.2963.2020.6023.95--132.550.532555.45-1.974.42-2.580.669521.45-5.29
Regenxbio Inc86.73m-260.15m611.27m344.00--1.56--7.05-5.88-5.881.967.970.126--5.00252,110.50-37.78-16.75-45.07-19.0856.8978.27-299.97-72.06----0.00---19.94-16.216.00---5.59--
GH Research PLC0.00-35.59m623.82m49.00--2.85-----0.6841-0.68410.004.210.00----0.00-14.81---15.16--------------0.0044-------58.47------
Mineralys Therapeutics Inc0.00-90.80m624.58m28.00--1.90-----2.18-2.180.006.610.00----0.00-27.78---29.11--------------0.00-------141.28------
Arrivent Biopharma Inc-100.00bn-100.00bn626.33m40.00--1.97----------9.49----------------------------0.00-------87.86------
Zentalis Pharmaceuticals Inc40.56m-218.90m627.76m168.00--1.37--15.48-3.36-3.360.59346.460.0775--7.09241,428.60-39.22-47.40-43.89-54.18-----506.16------0.00-------23.39--20.76--
ProKidney Corp0.00-35.30m632.54m163.00---------0.567-0.5670.00-17.790.00----0.00-30.32------------------0.0004------67.17------
Castle Biosciences Inc250.73m-30.80m632.76m610.00--1.57--2.52-1.15-1.159.2814.590.56648.017.12411,024.60-6.96-9.43-7.48-10.1780.5880.58-12.28-28.469.02--0.0243--60.3857.3514.41--117.94--
Harrow Inc138.68m-31.33m635.81m315.00--10.50--4.58-0.9079-0.90794.091.710.54064.216.75440,244.40-12.21-10.86-13.79-12.7169.7770.75-22.59-15.352.75-0.33020.7536--46.9525.77-73.30--143.88--
Zymeworks Inc50.46m-125.97m639.17m275.00--1.47--12.67-1.79-1.790.70866.150.0874--1.03185,529.40-21.82-22.58-24.45-26.90-----249.63-91.17----0.0002---81.577.47-195.44--3.58--
Sinovac Biotech Ltd448.27m-105.90m639.90m3.04k------1.43-1.08-1.084.1987.410.03231.130.9175147,602.60-1.8636.14-2.8058.3759.5190.77-57.6365.8710.18--0.0207---69.9714.31-198.16--91.80--
PetIQ Inc1.12bn7.34m642.04m1.93k100.082.7211.830.57330.21560.215636.407.951.294.585.67579,376.600.8933-4.321.14-5.2323.6620.050.6951-3.661.251.840.6517--19.5815.83104.42--4.96--
AnaptysBio Inc22.96m-163.30m649.36m117.00--13.59--28.28-6.13-6.130.8621.750.048--5.33196,256.40-34.11-18.08-36.72-18.96-----711.18-269.21----0.00--66.7827.97-27.11---5.36--
Lexicon Pharmaceuticals Inc2.31m-193.58m657.83m285.00--1.55--284.65-0.8257-0.82570.00981.170.008--2.598,108.77-66.76-24.41-72.21-29.0194.9898.49-8,376.55-84.9215.56-11.460.2569--766.19-54.71-73.74--37.68--
Phathom Pharmaceuticals Inc2.59m-246.63m664.37m452.00------256.12-4.41-4.410.047-2.540.0104----5,738.94-98.55-83.26-111.44-93.7777.14---9,507.71-135,982.007.80-5.291.46-------1.96------
Praxis Precision Medicines Inc2.20m-125.38m666.69m82.00--2.25--303.73-15.91-15.910.239417.320.0126----26,768.29-71.89-74.04-83.56-85.12-----5,711.85-24,589.25----0.00------42.40---4.52--
Data as of Feb 22 2019. Currency figures normalised to Sinovac Biotech Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
CDH Investment Advisory Pte. Ltd.as of 31 Mar 20246.00m0.00%
Renaissance Technologies LLCas of 31 Mar 20241.31m0.00%
Neumann Advisory Hong Kong Ltd.as of 31 Mar 2024315.59k0.00%
SSgA Funds Management, Inc.as of 31 Mar 2024160.88k0.00%
MW Gestion SAas of 31 Dec 202370.93k0.00%
The California Public Employees Retirement Systemas of 31 Mar 202468.73k0.00%
SEB Investment Management ABas of 31 Mar 202440.00k0.00%
Spark Investment Management LLCas of 31 Mar 202429.10k0.00%
Geode Capital Management LLCas of 31 Mar 202427.72k0.00%
Susquehanna Financial Group LLLPas of 31 Mar 202416.43k0.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.